Summary by Moomoo AI
Hansen Pharmaceutical Group Limited (the 'Company') announced its unaudited interim results for the six months ended June 30, 2024. During the period, the Company and its subsidiaries (collectively the 'Group') achieved a revenue of approximately RMB 6.506 billion, an increase of approximately 44.2% year-on-year; revenue from innovative drugs and collaborative products was approximately RMB 5.032 billion, an increase of approximately 80.6%, accounting for approximately 77.4% of the revenue; research and development expenses were approximately RMB 1.196 billion, an increase of approximately 28.7%, accounting for approximately 18.4% of the revenue; net profit was approximately RMB 2.726 billion, an increase of approximately 111.5%; basic earnings per share was approximately RMB 0.46, an increase of approximately 111.4%. The increase in revenue, net profit, and basic earnings per share during the period was mainly due to...Show More
Comment(0)
Reason For Report